Clinical commissioning policy: bedaquiline (B), pretomanid (Pa), linezolid (L) +/- moxifloxacin (M) (BPaLM/BPaL) for patients aged ≥14 years with suspected, functional or confirmed rifampicin resistant (RR) tuberculosis (TB), multidrug-resistant (MDR) TB or pre-extensively drug resistant (pre-XDR) TB [URN: 2310]

Document first published:
Page updated:
Topic:
Publication type:

Bedaquiline (B), pretomanid (Pa), linezolid (L) +/- moxifloxacin (M) (BPaLM/BPaL) is recommended to be available as a routine commissioning treatment option in patients aged ≥14 years old for suspected, functional or confirmed rifampicin resistant (RR) tuberculosis (TB), multidrug-resistant (MDR) TB and pre-extensively drug resistant (pre-XDR) TB within the criteria set out in this document.

The following documents may not be fully accessible for people using assistive technologies. If you would like to request a more accessible format, please email ENGLAND.CET@nhs.net

Document

Clinical commissioning policy BPaLM/BPaL for patients aged ≥14 years with suspected, functional or confirmed rifampicin resistant (RR) tuberculosis (TB), multidrug-resistant (MDR) TB or pre-extensively drug resistant (pre-XDR) TB

Clinical commissioning policy BPaLM/BPaL for patients aged ≥14 years with suspected, functional or confirmed rifampicin resistant (RR) tuberculosis (TB), multidrug-resistant (MDR) TB or pre-extensively drug resistant (pre-XDR) TB

  • PDF
  • 224 KB
  • 10 pages

Summary

Published 26 June 2024.

Document

Engagement report: BPaLM/BPaL for patients aged ≥14 years with suspected, functional or confirmed rifampicin resistant (RR) tuberculosis (TB), multidrug-resistant (MDR) TB or pre-extensively drug resistant (pre-XDR) TB

Engagement report: BPaLM/BPaL for patients aged ≥14 years with suspected, functional or confirmed rifampicin resistant (RR) tuberculosis (TB), multidrug-resistant (MDR) TB or pre-extensively drug resistant (pre-XDR) TB

  • PDF
  • 131 KB
  • 5 pages

Summary

Published 26 June 2024.

Document

Clinical Priorities Advisory Group summary report: BPaLM/BPaL for patients aged ≥14 years with suspected, functional or confirmed rifampicin resistant (RR) tuberculosis (TB), multidrug-resistant (MDR) TB or pre-extensively drug resistant (pre-XDR) TB

Clinical Priorities Advisory Group summary report: BPaLM/BPaL for patients aged ≥14 years with suspected, functional or confirmed rifampicin resistant (RR) tuberculosis (TB), multidrug-resistant (MDR) TB or pre-extensively drug resistant (pre-XDR) TB

  • PDF
  • 277 KB
  • 15 pages

Summary

Published 26 June 2024.

Document

Clinical Panel report: BPaLM/BPaL for patients aged ≥14 years with suspected, functional or confirmed rifampicin resistant (RR) tuberculosis (TB), multidrug-resistant (MDR) TB or pre-extensively drug resistant (pre-XDR) TB

Clinical Panel report: BPaLM/BPaL for patients aged ≥14 years with suspected, functional or confirmed rifampicin resistant (RR) tuberculosis (TB), multidrug-resistant (MDR) TB or pre-extensively drug resistant (pre-XDR) TB

  • PDF
  • 102 KB

Summary

Published 26 June 2024.

Document

Equality and health inequalities impact assessment: BPaLM/BPaL for patients aged ≥14 years with suspected, functional or confirmed rifampicin resistant (RR) tuberculosis (TB), multidrug-resistant (MDR) TB or pre-extensively drug resistant (pre-XDR) TB

Equality and health inequalities impact assessment: BPaLM/BPaL for patients aged ≥14 years with suspected, functional or confirmed rifampicin resistant (RR) tuberculosis (TB), multidrug-resistant (MDR) TB or pre-extensively drug resistant (pre-XDR) TB

  • PDF
  • 229 KB
  • 15 pages

Summary

Published 26 June 2024.

Document

NHS England evidence review: BPaLM/BPaL for patients aged ≥14 years with suspected, functional or confirmed rifampicin resistant (RR) tuberculosis (TB), multidrug-resistant (MDR) TB or pre-extensively drug resistant (pre-XDR) TB

NHS England evidence review: BPaLM/BPaL for patients aged ≥14 years with suspected, functional or confirmed rifampicin resistant (RR) tuberculosis (TB), multidrug-resistant (MDR) TB or pre-extensively drug resistant (pre-XDR) TB

  • PDF
  • 776 KB
  • 60 pages

Summary

Published 26 June 2024.